Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens.
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Despite the development of novel antibiotics active against Gram-positive bacteria, vancomycin generally remains the first treatment, although rapidly achieving concentrations associated with maximal efficacy provides an unresolved challenge. The objective of this study was to conduct a population pharmacokinetic analysis of vancomycin in a large population of critically ill patients. This was a retrospective data collection of 206 adult septic critically ill patients who were administered vancomycin as a loading dose followed by continuous infusion. The concentration-versus-time data for vancomycin in serum was analyzed by a nonlinear mixed-effects modeling approach using NONMEM. Monte Carlo simulations were performed using the final covariate model. We found that the best population pharmacokinetic model consisted of a one-compartment linear model with combined proportional and additive residual unknown variability. The volume of distribution of vancomycin (1.5 liters/kg) was described by total body weight and clearance (4.6 liters/h) by 24-hour urinary creatinine clearance (CrCl), normalized to body surface area. Simulation data showed that a 35-mg/kg loading dose was necessary to rapidly achieve vancomycin concentrations of 20 mg/liter. Daily vancomycin requirements were dependent on CrCl, such that a patient with a CrCl of 100 ml/min/1.73 m 2 would require at least 35 mg/kg per day by continuous infusion to maintain target concentrations. In conclusion, we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 2×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundAPACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Self-citationComparison of Dopamine and Norepinephrine in the Treatment of Shock
De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907118 · Cited by 1,940 · cited 1×
“The morbidity and mortality rates for sepsis and septic shock remain unacceptably high, with septic shock still associated with a 35 to 65% in-hospital mortality rate (5, 9).”
BackgroundSelf-citationInadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805 · cited 1×
“A significant body of work now describes the importance of early and appropriate antibiotic therapy as the intervention likely to minimize therapeutic failure (10, 17, 18).”
BackgroundRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795 · cited 2×
“The aim of this regimen was to provide serum drug concentrations between 20 and 30 mg/liter (28).”
BackgroundMethodAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Consensus supports the view that the pharmacokinetic-pharmacodynamic parameter best correlated with the efficacy of vancomycin is the AUC0–24-to-MIC (AUC0–24/ MIC) ratio (8, 11, 29).”
BackgroundPharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862 · cited 1×
“Augmented renal clearance is common in hyperdynamic critically ill patients and may increase the risk for subtherapeutic vancomycin exposure (27, 31).”
BackgroundSelf-citation
Research works printed but not linked: 1
- BealS. L. SheinerL. B.. 1998. NONMEM user guides (I-VIII). University of California at San Francisco, San Francisco, CA.
Cited by
Items 101–200 of 226
Advances in antibacterial treatment of adults with high-risk febrile neutropenia
Contejean, A., Maillard, A., Canouï, É., Kernéis, S., Fantin, B., Bouscary, D., Parize, P., García‐Vidal, C., & Charlier, C. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad166 · Cited by 19
Individualized antibiotic strategies
Taccone, F. S., Bond, O., Cavicchi, F. Z., & Hites, M. (2016) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000302 · Cited by 22
“Thereafter, higher than recommended drug regimens should be used for both aminoglycosides and vancomycin [35,36], whereas for b-lactam antibiotics, several studies have shown that continuous drug infusion (CI) can rapidly achieve adequate drug concentrations for all susceptible gram-negative strains [37,38].”
BackgroundSelf-citationGuo, T., van Hest, R. M., Zwep, L. B., Roggeveen, L. F., Fleuren, L. M., Bosman, R. J., van der Voort, P. H. J., Girbes, A. R. J., Mathôt, R. A. A., Elbers, P., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02908-7 · Cited by 18
Zhao, S., He, N., Zhang, Y., Wang, C., Zhai, S., & Zhang, C. (2021) · Antibiotics · doi:10.3390/antibiotics10101238 · Cited by 19
Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia
Hochart, C., Berthon, C., Corm, S., Gay, J., Cliquennois, M., Tricot, S., & Alfandari, S. (2011) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2011.09.014 · Cited by 18
“Recent data for intensive care patients support using body weight adjusted loading doses, but suggest that, to achieve a rapid and durable 20 mg/L vancomycin concentration, 35 mg/kg should be used as a loading dose and as daily continuous infusion maintenance therapy [14].”
BackgroundMethodLacave, G., Caille, V., Bruneel, F., Palette, C., Legriel, S., Grimaldi, D., Eurin, M., & Bédos, J. (2017) · Medicine · doi:10.1097/md.0000000000006023 · Cited by 18
Pongchaidecha, M., Changpradub, D., Bannalung, K., Seejuntra, K., Thongmee, S., Unnual, A., & Santimaleeworagun, W. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.4.573 · Cited by 17
“performed blood samples for vancomycin measurement taken every day [14, 15].”
BackgroundStockmann, C. R., Roberts, J. K., Tian, Y., Constance, J. E., Knibbe, C. A. J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.966081 · Cited by 16
“Additionally, varying volume of distribution estimates have been reported [87,136].”
BackgroundSelf-citationAssessing the performance of QSP models: biology as the driver for validation
Singh, F. A., Afzal, N., Smithline, S. J., & Thalhauser, C. J. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09871-x · Cited by 15
Terms of use of outpatient parenteral antibiotic therapy
Diamantis, S., Longuet, P., Lesprit, P., & Gauzit, R. (2020) · Infectious Diseases Now · doi:10.1016/j.medmal.2020.06.004 · Cited by 15
Belabbas, T., Yamada, T., Egashira, N., Hirota, T., Suetsugu, K., Mori, Y., Kato, K., Akashi, K., & Ieiri, I. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.01.010 · Cited by 18
Antibiotic dosing in obesity: a BIG challenge
Hanrahan, T. P., Lipman, J., & Roberts, J. A. (2016) · Critical Care · doi:10.1186/s13054-016-1426-y · Cited by 15
“These data are similar to recent findings in non-obese critically ill populations [12], although there are ultimately many ill-defined variables that preclude direct extrapolation of non-obese data.”
ResultSelf-citationTherapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients
Gorham, J., Taccone, F. S., & Hites, M. (2023) · Antibiotics · doi:10.3390/antibiotics12071099 · Cited by 14
“The SDR of vancomycin is a LD of 30–35 mg/kg followed by a maintenance dose (MD) based on creatinine clearance (CrCL) and TDM [62,63].”
MethodSelf-citationAntibiotic dosing for multidrug-resistant pathogen pneumonia
Abdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000348 · Cited by 17
Self-citationSistanizad, M., Hassanpour, R., & Pourheidar, E. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/1867674 · Cited by 14
“…proposed that an LD of 35 mg/kg vancomycin followed by continuous infusion of 35 mg/kg/day needs to keep the vancomycin trough concentration within the target therapeutic range in the CrCl equal to 100 ml/min/1.73 m 2 and higher CrCls need the larger MD to maintain the therapeutic exposure [35].”
InfluentialUster, D. W., & Wicha, S. G. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12782 · Cited by 17
Approaches for dosage individualisation in critically ill patients
de Gatta, M. A. D. M. F., Martín‐Suárez, A., & Lanao, J. M. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.822486 · Cited by 15
“Multiple model Bayesian Structural models One-compartment [68] Two-compartments [69-71] Three-compartments [65,67] PK/PD models [66,67,72] Variability models Exponential [64,71,74,76] Exponential-additive [75,76] Constant coefficient of variation [77]”
MethodSynthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling
Chan, A., Peck, R., Gibbs, M. A., & van der Schaar, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12965 · Cited by 18
Closed-Loop Control for Precision Antimicrobial Delivery: An In Silico Proof-of-Concept
Herrero, P., Rawson, T. M., Philip, A., Moore, L. S. P., Holmes, A. H., & Georgiou, P. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2787423 · Cited by 16
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment
Gorham, J., Taccone, F. S., & Hites, M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2056012 · Cited by 14
“if vancomycin is administered as continuous infusion, steady-state concentrations should be measured daily and kept at 25 mg/L, which corresponds to an adequate AUC/ MIC to treat Staphylococcus aureus [113] and a reduced risk”
BackgroundSelf-citationYu, Z., Liu, J., Yu, H., Zhou, L., Zhao, Y., Zhong, L., Jianping, Z., Liang, G., Yang, Y., Zheng, Y., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106812 · Cited by 12
Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring
Aljutayli, A., Thirion, D. J. G., & Nekka, F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113777 · Cited by 12
Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing
Pletz, M. W., & Lipman, J. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-2918-8 · Cited by 12
“Finally, besides ARC, an increased volume of distribution (Vd) can contribute to low vancomycin concentrations [14].”
BackgroundSelf-citationMaung, N. H., Methaneethorn, J., Wattanavijitkul, T., & Sriboonruang, T. (2021) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2020-002637 · Cited by 11
A Free Open-Source Bayesian Vancomycin Dosing App for Adults: Design and Evaluation Study
Oommen, T., Thommandram, A., Palanica, A., & Fossat, Y. (2022) · JMIR Formative Research · doi:10.2196/30577 · Cited by 13
“The Adane et al [11] model is reserved for patients with a BMI greater than 40 kg/m(2) and body weight over 120 kg, while the Robers et al [13] model is reserved for the critically ill.”
BackgroundMethodResultInfluentialZhang, R., Chen, M., Liu, T.-T., Lu, J., & Lv, C. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00578-4 · Cited by 11
Mahmoud, A. A., Avedissian, S. N., Al‐Qamari, A., Bohling, T., Pham, M. M., & Scheetz, M. H. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00902-1 · Cited by 13
Wolff, M., & Mourvillier, B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis330 · Cited by 11
Viertel, K., Feles, E. A., Schulte, M., Annecke, T., & Mattner, F. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107005 · Cited by 11
Eldemiry, E. M. B., Sabry, N. A., Abbassi, M., Abdelshafy, S., Mokhtar, M., & Bary, A. A. (2013) · SAGE Open Medicine · doi:10.1177/2050312113507921 · Cited by 10
A new approach to Vancomycin utilization evaluation: A cross-sectional study in intensive care unit
Farsaei, S., Mahmoodian, A., & Abbasi, S. (2016) · Journal of Research in Pharmacy Practice · doi:10.4103/2279-042x.192453 · Cited by 10
“In Intensive Care Units (ICUs) the risk of methicillin‐resistant Staphylococcus aureus (MRSA) infections have considerably increased in recent years, which can lead to the development of sepsis or septic shock and subsequently high rate of morbidity and mortality.[1,2] Data from the previous studies showed 5–16% of cr…”
BackgroundResultHow should we dose antibiotics for pneumonia in the ICU?
Udy, A. A., Roberts, J. A., & Lipman, J. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835d19e0 · Cited by 11
Self-citationSin, J. H., Newman, K. A., Elshaboury, R. H., Yeh, D. D., de Moya, M. A., & Lin, H. H. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx356 · Cited by 10
Mena, M., Casallas, J. C. G., & Bustos, R. (2023) · Antibiotics · doi:10.3390/antibiotics12020301 · Cited by 10
“[50] are clinically appropriate to inform vancomycin dosing in critically ill patients, and the Goti model was the only clinically acceptable model with both a priori (rBias 3.”
MethodTaheri, M. S., Dadashzadeh, S., Shokouhi, S., Ebrahimzadeh, K., Sadeghi, M., & Sahraei, Z. (2018) · PubMed Central · Cited by 10
An optimal antibiotic selection framework for Sepsis patients using Artificial Intelligence
Wendland, P., Schenkel-Häger, C., Wenningmann, I., & Kschischo, M. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01350-y · Cited by 12
“MostdosingregimesaimtoachieveVancomycinserumlevelsof 20 – 30 μ g/mL and depend on the patient ’ s weight or comorbidities, but they vary in terms of dose adjustment 39 – 41 .”
Baptista, J. P. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_7 · Cited by 10
Vancomycin Adsorption During in vitro Model of Hemoperfusion with HA380 Cartridge
Godi, I., Lorenzin, A., Rosa, S. D., Golino, G., Knust, M., Gaspar, A., Sandini, A., Fiorin, F., de Cal, M., Navalesi, P., et al. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000513122 · Cited by 9
Optimization of antibiotic therapy in the obese, critically ill patient
Hites, M., & Taccone, F. (2015) · Réanimation · doi:10.1007/s13546-015-1060-8 · Cited by 9
“75 g in 4 h every 8 h Doripenem: 500 mg in 4 h infusions every 8 h Meropenem: 1 g every 6 h or 2 g every 8 h Aminoglycosides Gentamycin Loading dose of 7–8 mg/kg based on ABW, followed by TDM-based dose adjustment [79,83] Tobramycin Loading dose of 7–8 mg/kg based on ABW, followed by TDM-based dose adjustment [79,83]…”
MethodSelf-citationPerin, N., Roger, C., Marin, G., Molinari, N., Evrard, A., Lavigne, J., Barbar, S. D., Claret, P. G., Boutin, C., Müller, L., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9110793 · Cited by 9
“8)) relative to the recommended dose (25–30 mg/kg) [5,15,35].”
BackgroundSelf-citationPopulation pharmacokinetics of antibacterial agents in the older population: a literature review
Liu, H., Tang, B., van den Anker, J., Hao, G., Zhao, W., & Zheng, Y. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2295009 · Cited by 8
Bédos, J., Allaouchiche, B., Armand-Lefèvre, L., Baldési, O., Bouadma, L., Decré, D., Figueiredo, S., Gauzit, R., Guery, B. P., Joram, N., et al. (2014) · Réanimation · doi:10.1007/s13546-014-0916-7 · Cited by 11
Selig, D. J., Reed, T. J., Chung, K. K., Kress, A. T., Stewart, I. J., & DeLuca, J. P. (2022) · Blood Purification · doi:10.1159/000524457 · Cited by 8
Taccone, F. S., Vincent, J., Denis, O., & Jacobs, F. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis332 · Cited by 8
Self-citationChang, J. H. T., Pais, G. M., Engel, P. L., Klimek, P., Marianski, S., Valdez, K., & Scheetz, M. H. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01276-22 · Cited by 7
24/7 Therapeutic Drug Monitoring of Beta-Lactam Antibiotics with CLAM-2000
Khromov, T., Dihazi, G. H., Brockmeyer, P., Fischer, A., & Streit, F. (2023) · Antibiotics · doi:10.3390/antibiotics12101526 · Cited by 9
“This is true not only for beta-lactam antibiotics [15,16] but also for aminoglycosides [20], glycopeptides [21], fluoroquinolones [22], and oxazolidinones [23].”
BackgroundSong, X., Zeng, M., Wu, Y. P., & Pan, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.649757 · Cited by 8
van Maarseveen, E. M., Bouma, A., Touw, D. J., Neef, C., & van Zanten, A. R. H. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1742-6 · Cited by 10
“[28].”
Timofte, I., Terrin, M. L., Barr, E. A., Kim, J., Rinaldi, J., Ladikos, N., Menaker, J. A., Tabatabai, A., Kon, Z. N., Griffith, B. P., et al. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.07.033 · Cited by 7
“Although the underling mechanisms are not clearly defined, numerous pharmacokinetic studies have demonstrated interactions between patient characteristics, pathology and drug levels [3-6].”
BackgroundWestra, N., Kruithof, P. D., Croes, S., van Geel, R. M. J. M., Hendriks, L. E. L., Touw, D. J., Munnink, T. H. O., & Mian, P. (2024) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-024-00904-5 · Cited by 6
“The validation of the osi-mertinib popPK models was carried out comparably to validations of popPK models for different drugs [11–13].”
MethodPredictive Performance of Bayesian Dosing Software for Vancomycin in Intensive Care Unit Patients
Bai, G., Qi, H., Huang, Y., Zhang, J., Zhao, H., Wen, R.-T., & Zhang, X. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001310 · Cited by 9
“17 – 19 Among these, the models of Goti et al, 20 Thomson et al, 21 and Roberts et al 22 exhibited the best predictions.”
Song, X., & Han, M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.874401 · Cited by 8
Review and evaluation of vancomycin dosing guidelines for obese individuals
Wong, S., Reuter, S. E., Jones, G. R. D., & STOCKER, S. L. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2098106 · Cited by 6
“guidelines specify higher loading doses of 20–35 mg/kg for critically ill patients [1], due to reportedly larger volume of distribution and augmented drug clearance in these individuals [93,94].”
BackgroundA simulation of loading doses for vancomycin continuous infusion regimens in intensive care
Šíma, M., Hronová, K., Hartinger, J. M., & Slanař, O. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1328741 · Cited by 8
“Higher Vd values would be expected especially in critically ill septic patients [31].”
BackgroundSitaruno, S., Santimaleeworagun, W., Pattharachayakul, S., DeBacker, K. C., Vattanavanit, V., Binyala, W., & Pai, M. P. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2070 · Cited by 6
“The Journal of Clinical Pharmacology 2022, 62(10) 1215–1226 © 2022, The Authors.”
BackgroundGastmans, H., Dreesen, E., Wicha, S. G., Dia, N., Spreuwers, E., Dompas, A., Allegaert, K., Desmet, S., Lagrou, K., Peetermans, W. E., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071459 · Cited by 10
Guo, T., van Hest, R. M., Fleuren, L. M., Roggeveen, L. F., Bosman, R. J., van der Voort, P. H. J., Girbes, A. R. J., Mathôt, R. A. A., van Hasselt, J. G. C., & Elbers, P. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14498 · Cited by 6
“A previously published one-compartmental PopPK model of vancomycin (Table 1) was adopted to execute both the PK simulation and MAP estimation in this study.(15) The model has been validated in our own ICU population, which turned out to best describe our data among all identified candidate models.”
MethodSafety considerations of current drug treatment strategies for nosocomial pneumonia
Ceccato, A., Giannatale, P. D., Nogas, S., & Torres, A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1857362 · Cited by 7
Karimian, A., Karimzadeh, I., Shafiekhani, M., Heidari, R., Masjedi, F., Izadi, F., Barshan-Tashnizi, N., Kane‐Gill, S. L., & Mahmoudi, L. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03372-5 · Cited by 5
“…of suspected or known infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or coagulase-negative staphylococci (CONS) in critically ill Extended author information available on the last page of the article patients (Murray et al. 2015; Roberts et al. 2011 ; Kan et al. 2022).”
Setiawan, E., Cotta, M. O., Roberts, J. A., & Abdul-Aziz, M. H. (2023) · Antibiotics · doi:10.3390/antibiotics12050803 · Cited by 6
“Comparator ICU patients [68] One (2–3) 1.”
BackgroundInfluentialSelf-citationKarimzadeh, I., Kane‐Gill, S. L., & Ma, B. (2025) · Antibiotics · doi:10.3390/antibiotics14111138 · Cited by 7
Hannan, K. N. A., Rivera, C. G., & Fewel, N. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac372 · Cited by 4
(SRLF), S. D. R. D. L. F., (Sfar), S. F. D.-R., & Bretonnière, C. (2015) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2015.06.001 · Cited by 5
“d’obtenir immédiatement cette cible [126].”
BackgroundInfluentialChemical pharmacotherapy for hospital-acquired pneumonia in the elderly
Burgos, J., Falcó, V., & Almirante, B. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1559820 · Cited by 4
Xu, K.-Y., Li, D., Hu, Z., Zhao, C., Bai, J., & Du, W.-L. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i18.6218 · Cited by 4
Ng, T. M., Lye, D. C., Chan, M., & Tam, V. H. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.007 · Cited by 4
Fakultas Farmasi, U. S., Setiawan, E., Widyati, Rumah Sakit TNI Angkatan Laut dr. Ramelan, S., Marpaung, F. R., Airlangga, D. P. K. R. D. S. K. U., Rumah Sakit PHC, S., Sukandar, E., Rumah Sakit Umum Moh. Dr. Soewandhie, S., Susaniwati, et al. (2019) · Pharmaceutical Sciences and Research · doi:10.7454/psr.v6i1.4274 · Cited by 4
Self-citationAcute Kidney Injury and Renal Replacement Therapy
Choi, G. Y. S., & Joynt, G. M. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_6 · Cited by 4
Hirunsomboon, C., Pathumarak, A., Nosoongnoen, W., Tharanon, V., & Sukkha, S. (2026) · Clinical and Translational Science · doi:10.1111/cts.70511 · Cited by 3
Romdhane, H. B., Woillard, J., Fadhel, N. B., Chadli, Z., Chaabane, A., Boughattas, N. A., Fredj, N. B., & Aouam, K. (2024) · Pharmacology · doi:10.1159/000539866 · Cited by 3
“While Vu et al. [21] did not show a weight in fl uence on Vd, many other studies have identi fi ed body weight as a signi fi cant covariate in their Pop Pk models [15, 16, 19, 34].”
InfluentialAntibiotic Dosing During Extracorporeal Membrane Oxygenation
Abdul-Aziz, M. H., Shekar, K., & Roberts, J. A. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_8 · Cited by 3
Self-citationIn silico Evaluation of a Vancomycin Dosing Guideline Among Adults with Serious Infections
Williams, P. G., Cotta, M. O., Abdul-Aziz, M. H., Wilks, K. M., Farkas, A., & Roberts, J. A. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001102 · Cited by 3
Self-citationSuzuki, M., Kasai, H., Aoyama, T., & Tsuji, Y. (2025) · Pharmaceuticals · doi:10.3390/ph18111748 · Cited by 2
“The VCM blood sampling times from six studies [18,19,23,25,27,31] included only trough samples, whereas the remaining 13 studies included blood sampling data at peak or random time points.”
InfluentialDia, N., Hoffert, Y., Edwina, A. E., Tournoy, J., Spriet, I., & Dreesen, E. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01638-0 · Cited by 2
“[22, 34–36, 38, 39, 51, 58, 60, 66, 67, 75, 78, 84, 116, 117, 130] (Tables S5, S9 and S12).”
InfluentialHusheng, H., Ying, W., He, Y., Shen, F., & Chen, J. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s603150 · Cited by 2
Gilliot, S., Boukhris, M. R., Masse, M., Storme, L., Décaudin, B., Odou, P., & Duc, K. L. (2021) · BMC Pediatrics · doi:10.1186/s12887-021-02824-8 · Cited by 4
Alsultan, A., Dasuqi, S. A., Almohaizeie, A., Aljutayli, A., Aljamaan, F., Omran, R. A., Alolayan, A., Hamad, M. A., Alotaibi, H. F., Altamimi, S. A., et al. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2375 · Cited by 2
“49,52 In total, 10 studies were included (Tables 2 and 3): 4 studies in patients who are obese, 38–41 5 studies in critically ill patients, 46–48, 52”
BackgroundPharmacokinetic behavior presents drug therapy challenges
Slaughter, R. L. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.849196 · Cited by 2
Trouillet, J. L., & Chastre, J. E. (2013) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2013.04.003 · Cited by 2
Nikolić, A., Jaćović, S., Mijailović, Ž., & Petrović, D. (2019) · EABR. Experimental and Applied Biomedical Research · doi:10.2478/sjecr-2018-0071 · Cited by 2
“1 L/kg and plasma protein binding percentage - PB = 10-50% [51-53].”
BackgroundInfluentialAttainment of therapeutic vancomycin level within the first 24 h
Honoré, P. M., Bels, D. D., Attou, R., Redant, S., Gallerani, A., & KASHANI, K. B. (2019) · Critical Care · doi:10.1186/s13054-019-2515-5 · Cited by 2
PK / PD and the Drug Delivery Regimen for Infusion in the Critical Care Setting
Sime, F. B., & Roberts, J. A. (2021) · Wiley eBooks · doi:10.1002/9781119772767.ch10 · Cited by 2
Self-citationPharmacokinetics and Pharmacodynamics of Antibiotics in Transplant Patients
Schoeppler, K. E., Mueller, S. W., & Barber, G. R. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_51 · Cited by 2
Infecciones en pacientes con tumores sólidos de sistema nervioso central y de cabeza y cuello
Costantini, P., & Mora, A. (2018) · Actualizaciones en Sida e Infectología · doi:10.52226/revista.v26i97.25 · Cited by 1
Holub, L., Karvaly, G., Závorszky, L., Kristóf, K., Tóth, Á., Tóth, K., Lovász, B., Kassa, C., Vásárhelyi, B., Lakatos, B., et al. (2025) · Orvosi Hetilap · doi:10.1556/650.2025.33279 · Cited by 1
Petitjean, O., & Gauzit, R. (2013) · Références en réanimation · doi:10.1007/978-2-8178-0389-0_6 · Cited by 1
Pokhriyal, S. C., Tan, E. F. S., Bhatt, P. K., Khan, A. A., Pasha, M. N., Pierre, L., & Panigrahi, K. (2024) · Cureus · doi:10.7759/cureus.61943 · Cited by 1
Pharmacodynamic Considerations in Critically Ill Patients
Sinnollareddy, M., & Roberts, J. A. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_21 · Cited by 1
Self-citationPhysiological Manifestations of Critical Illness
Pea, F. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_3 · Cited by 1
Pharmacokinetic and Pharmacodynamic Tools to Increase Efficacy
Sinnollareddy, M., Cotta, M. O., & Roberts, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-810477-4.00007-6 · Cited by 1
Self-citationReply to Taccone et al, Wolff and Mourvillier, Masuta and Iwata, and Lahey
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., & Chastre, J. E. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis334 · Cited by 1
“These recommendations were based on Monte Carlo simulation rather than an actual clinical trial [9].”
MethodLipman, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4762-6.00072-2 · Cited by 1
Self-citationWhat’s New in the Recognition and Management of Septic Shock in Children: Dos and Don'ts
Argent, A. C. (2013) · Current Pediatrics Reports · doi:10.1007/s40124-012-0007-z
Wolff, M. (2012) · Réanimation · doi:10.1007/s13546-012-0471-z
“L’utilisation d’une dose de charge de 30-35 mg/kg suivie d’une perfusion continue de même posologie par 24 heures chez des patients ayant une fonction rénale normale peut être nécessaire pour assurer ces objectifs [12].”
BackgroundHanrahan, T. P., Harlow, G., Dulhunty, J. M., Lipman, J., Whitehouse, T., & Roberts, J. A. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000000952
Self-citationAlobaid, A. S. (2016) · The University of Queensland · doi:10.14264/uql.2016.765
Antibiotics in critical care: dosing, therapeutic drug monitoring and continuous infusions
Hites, M., & Taccone, F. S. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004516
Self-citationA Review of Vancomycin Population Pharmacokinetic Studies in Adult Critically Ill Patient
Setiawan, E., & Montakantikul, P. (2012) · ASEAN/Asian Academic Society International Conference (AASIC) Proceeding Series (Indonesian Student Association in Thailand (Permitha))
Generic and Optimized Antibacterial Dosing Strategies in the Critically Ill
Waele, J. J. D. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_10
Appropriate Antimicrobial Therapy in Critically Ill Patients
Sime, F. B., & Roberts, J. A. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_21
Self-citation
Metadata
- Authors
- Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Roberts, Jason A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-06
- Volume
- 55
- Issue
- 6
- Pages
- 2704-2709
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3101407
- OpenAlex
- W2161342563
- Semantic Scholar
- 6a21d1534090532b1e164a9fa3b5932d1c6a8db8
- Cited by
- 226
- References
- 35
- Citations by year
- 2026: 14 · 2025: 5 · 2024: 9 · 2023: 16 · 2022: 19 · 2021: 12 · 2020: 18 · 2019: 14 · 2018: 8 · 2017: 21 · 2016: 15 · 2015: 9 · 2014: 18 · 2013: 25 · 2012: 18
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- vancomycin, population pharmacokinetics, continuous infusion, critically ill patients, sepsis, loading dose, renal clearance, creatinine clearance, dose adjustment, target attainment, Gram-positive bacterial infections, Monte Carlo simulation
- MeSH terms
- Adult, Aged, Anti-Bacterial Agents, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Retrospective Studies, Vancomycin, Critical Illness, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.